Protalix BioTherapeutics
PLX
PLX
34 hedge funds and large institutions have $7.6M invested in Protalix BioTherapeutics in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
0.03% more ownership
Funds ownership: 0.68% → 0.72% (+0.03%)
34% less capital invested
Capital invested by funds: $11.5M → $7.6M (-$3.89M)
Holders
34
Holding in Top 10
–
Calls
$202K
Puts
$174K
Top Buyers
| 1 | +$591K | |
| 2 | +$576K | |
| 3 | +$313K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$309K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$272K |
Top Sellers
| 1 | -$2.14M | |
| 2 | -$166K | |
| 3 | -$142K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$139K |
| 5 |
Jane Street
New York
|
-$98.8K |